<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821105</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0375</org_study_id>
    <secondary_id>NCI-2012-01242</secondary_id>
    <nct_id>NCT01821105</nct_id>
  </id_info>
  <brief_title>2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer</brief_title>
  <official_title>A 2 Phase Comparison of Pre-operative CT AND PET Images in the Intraoperative Detection of Disease to a Hand-held Probe, and to an Intraoperative CT Scan in Patients Undergoing Surgery for Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase II studies how well computed tomography (CT) and positron emission
      tomography (PET) imaging works in detecting disease in patients undergoing surgery for
      metastatic colorectal cancer. Diagnostic procedures, such as CT and PET scans, done before
      and during surgery may help find colorectal cancer and help guide surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the feasibility of rigidly (linearly) registering PET to CT images and
      applying this fused dataset to guide surgery with an image-guided navigation system and a
      handheld positron probe in order to facilitate disease detection and improve resection
      accuracy in advanced stage colorectal cancer.

      II. To complete development of software for the nonlinear registration of PET and CT
      datasets.

      OUTLINE:

      Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis.
      Patients then receive 18 F fludeoxyglucose (FDG) intravenously (IV) 60-90 minutes prior to
      surgery and undergo intraoperative CT scans using a handheld probe and computer navigation
      system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of Position Accuracy With Handheld Probe on Anatomical Location.</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Adverse Events and Complications</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Detection</measure>
    <time_frame>At surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage IV A Bladder Cancer</condition>
  <condition>Stage IV A Rectal Cancer</condition>
  <condition>Stage IV B Colon Cancer</condition>
  <condition>Stage IV B Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Preoperative PET and CT Scans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET Scan</intervention_name>
    <description>All patients will receive whole body PET scans (chest-abdomen-pelvis).</description>
    <arm_group_label>Preoperative PET and CT Scans</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CT Scan</intervention_name>
    <description>All patients will receive CT scans of the abdomen and pelvis with contrast.</description>
    <arm_group_label>Preoperative PET and CT Scans</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Preoperative PET and CT Scans</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computer-aided detection/diagnosis</intervention_name>
    <description>Undergo computer-aided detection/diagnosis during surgery</description>
    <arm_group_label>Preoperative PET and CT Scans</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically-confirmed colorectal carcinoma and preoperative PET scan
             with evidence of hypermetabolic lesions suspicious for cancer will be eligible for
             this study. In cases of primary cancer, there must be a tissue-confirmed diagnosis. In
             recurrent cases, patients must have clinical evidence by CT or MRI of disease suitable
             for resection.

          -  Patients must be candidates for clinically indicated surgery.

          -  Patients with recurrent disease may have had prior surgery and/or chemotherapy with no
             limit to the number of prior therapeutic procedures or chemotherapeutic regimens.

          -  Patients must have a performance status of 0, 1 or 2 by ECOG(Eastern Cooperative
             Oncology Group)standards.

          -  Patients must give written informed consent including consent to have IV line placed
             for FDG administration.

          -  Patients must be at least 18 years of age. Children under the age of 18 are excluded
             from the study due to the rarity of colorectal cancer in children.

          -  Because radiolabeled agents are known to be teratogenic, women of child-bearing
             potential and men must agree to use an acceptable form of contraception prior to study
             entry and for the duration of the study participation. Should a woman become pregnant
             or suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately.

          -  Organ function requirements: Patients must have organ and marrow function adequate to
             undergo laparotomy. Specifically:

          -  Serum creatinine &lt; 2.0 mg/dl

          -  Serum bilirubin &lt; 2.0 mg/dl

          -  AST(aspartate aminotransferase,serum glutamate oxaloacetate transaminase, serum
             glutamate oxaloacetate transaminase,serum glutamate pyruvate
             transaminase)[SGOT]/ALT[SGPT]&lt;4 times institutional upper limit of normal

          -  Total WBC(white blood cell)&gt;4,000/mm3 or ANC(absolute neutrophil count)&gt; 1,500/mm3

          -  Platelets &gt; 100,000/mm3

          -  Hgb &gt;10g/dl

          -  Patient must have no clinically significant cardiac disease (New York Heart
             Association Class III/IV); no serious infection requiring treatment with antibiotics;
             no other serious ill-ness or illness requiring the use of steroids; no clinically
             significant pulmonary disease or other illness that would contraindicate or increase
             the risk of complications at surgery.

          -  Fasting blood sugar less than 120 mg/dl

        Exclusion Criteria:

          -  Patients with active CNS (central nervous system)tumor involvement are ineligible.

          -  Any patient who has retained childbearing potential will not be pregnant or lactating
             and must use adequate contraception to assure avoidance of conception.

          -  Body size prohibits use of the diagnostic equipment (portable CT scanner).

          -  Tumor burden is so great (as determined by preoperative PET scanning or intraoperative
             findings) that further surgery is not advised.

          -  If lesions are detected with preoperative CT but not with PET scanning (in other
             words, all patients will have a positive PET scan as part of the inclusion criteria).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Sarikaya I, Povoski SP, Al-Saif OH, Kocak E, Bloomston M, Marsh S, Cao Z, Murrey DA, Zhang J, Hall NC, Knopp MV, Martin EW Jr. Combined use of preoperative 18F FDG-PET imaging and intraoperative gamma probe detection for accurate assessment of tumor recurrence in patients with colorectal cancer. World J Surg Oncol. 2007 Jul 16;5:80.</citation>
    <PMID>17634125</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <results_first_submitted>November 23, 2015</results_first_submitted>
  <results_first_submitted_qc>December 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Edward Martin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>computed tomography</keyword>
  <keyword>CT scan</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>PET</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Preoperative PET and CT Scans</title>
          <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
PET Scan: All patients will receive whole body PET scans (chest-abdomen-pelvis).
CT Scan: All patients will receive CT scans of the abdomen and pelvis with contrast.
fludeoxyglucose F 18: Given IV
computer-aided detection/diagnosis: Undergo computer-aided detection/diagnosis during surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preoperative PET and CT Scans</title>
          <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
PET Scan: All patients will receive whole body PET scans (chest-abdomen-pelvis).
CT Scan: All patients will receive CT scans of the abdomen and pelvis with contrast.
fludeoxyglucose F 18: Given IV
computer-aided detection/diagnosis: Undergo computer-aided detection/diagnosis during surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="31" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean time interval from initial treatment to PET scan</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="3" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean time interval from PET scan to surgery/GP study</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="1" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Detection of Position Accuracy With Handheld Probe on Anatomical Location.</title>
        <time_frame>up to 12 months</time_frame>
        <population>number of tumor lesions detected by the probe</population>
        <group_list>
          <group group_id="O1">
            <title>Preoperative PET and CT Scans</title>
            <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
PET Scan: All patients will receive whole body PET scans (chest-abdomen-pelvis).
CT Scan: All patients will receive CT scans of the abdomen and pelvis with contrast.
fludeoxyglucose F 18: Given IV
computer-aided detection/diagnosis: Undergo computer-aided detection/diagnosis during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Detection of Position Accuracy With Handheld Probe on Anatomical Location.</title>
          <population>number of tumor lesions detected by the probe</population>
          <units>lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>true postive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>false positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Adverse Events and Complications</title>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preoperative PET and CT Scans</title>
            <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
PET Scan: All patients will receive whole body PET scans (chest-abdomen-pelvis).
CT Scan: All patients will receive CT scans of the abdomen and pelvis with contrast.
fludeoxyglucose F 18: Given IV
computer-aided detection/diagnosis: Undergo computer-aided detection/diagnosis during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>All Adverse Events and Complications</title>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Detection</title>
        <time_frame>At surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preoperative PET and CT Scans</title>
            <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
PET Scan: All patients will receive whole body PET scans (chest-abdomen-pelvis).
CT Scan: All patients will receive CT scans of the abdomen and pelvis with contrast.
fludeoxyglucose F 18: Given IV
computer-aided detection/diagnosis: Undergo computer-aided detection/diagnosis during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Detection</title>
          <units>lesions detected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Preoperative PET and CT Scans</title>
          <description>Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
PET Scan: All patients will receive whole body PET scans (chest-abdomen-pelvis).
CT Scan: All patients will receive CT scans of the abdomen and pelvis with contrast.
fludeoxyglucose F 18: Given IV
computer-aided detection/diagnosis: Undergo computer-aided detection/diagnosis during surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Martin, MD</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-293-8843</phone>
      <email>Edward.Martin@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

